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Summary 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variable clinical presentation that ranges 
from asymptomatic, to severe disease with cytokine storm. The mortality rates also differ across the globe, 
ranging from 0.5-13%. This variation is likely due to both pathogen and host factors. Host factors may include 
genetic differences in the immune response genes as well as variation in HLA and KIR allotypes. To better 
understand the what impact these genetic variants in immune response genes may have in the differences 
observed in the immune response to SARS-CoV-2, a quantitative analysis of a dynamical systems model that 
considers both, the magnitude of viral growth, and the subsequent innate and adaptive response required to 
achieve control of infection is considered. Based on this broad quantitative framework it may be posited that 
the spectrum of symptomatic to severely symptomatic presentations of COVID19 represents the balance 
between innate and adaptive immune responses. In asymptomatic patients prompt and adequate adaptive 
immune response quells infection, whereas in those with severe symptoms a slower inadequate adaptive 
response leads to a runaway cytokine cascade fueled by ongoing viral replication. Polymorphisms in the various 
components of the innate and adaptive immune response may cause an altered immune response kinetics that 
would result in variable severity of illness. Understanding how this genetic variation may alter the response to 
SARS-CoV-2 infection is critical to develop successful treatment strategies.  
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Introduction 
The coronavirus disease 2019 (COVID-19) pandemic of 2020 has created a challenge to humanity like none other 
in recent times. With its global reach, infections with the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) have exacted a tremendous toll from populations around the world. This single-stranded RNA virus 
gains access to the host intracellular milieu through interaction with the angiotensin-converting enzyme 2 (ACE-
2) which is expressed on a variety of epithelial and endothelial cells.1 2 Not only is this novel virus associated with 
higher mortality than other respiratory viruses, such as influenza, but it also demonstrates a broader variation in 
its clinical presentation.3 4 5 6 At disease onset, the symptoms are generally mild and restricted to the respiratory 
tract. Still, later, secondary viremia may involve other organ systems expressing ACE-2, including the 
cardiovascular, nervous, and renal systems.7 Several patients experience an exaggerated immune response in 
the form of cytokine release syndrome.8 9 Despite this, a vast majority of patients with COVID-19 may be 
asymptomatic or only mildly symptomatic, with the remainder experiencing a range of clinical manifestations, 
from moderate-to-severe, life-threatening.7 Mortality rates are high in the elderly and those with comorbidities. 
Still, the young and otherwise healthy may also develop severe disease.10 11 There is wide variability in case-
fatality rates in different populations around the United States (Figure 1A) and the world, with rates as high as 
10-13% seen in Italy, England, and Spain, but as low as 0.5-2% in Iceland, Norway and Japan (Figure 1 B). This 
variation in the global death toll from this infection, despite testing and reporting biases, may suggest a genetic 
component in disease susceptibility. This variation may represent differences in the relative proportions of 
tested versus non-tested populations, socio-economic, comorbid conditions, and differential public health 
practices. It may be postulated that the disparity in disease severity could be at least in part due to genetic 
differences in the innate and adaptive immune responses that individuals may mount to SARS-CoV-2.12  
Immune Response to SARS-CoV-2, a general overview 
COVID19 symptomatology may be due to a combination of pathogen and host factors. Progression to the more 
severe forms of disease not only dependent on pathogen factors such as viral inoculum and virulence but, most 
likely, also on host factors that lead to variable immune response. Patients with adequate immune function 
likely contain the virus without over-reaction.11 However, in those with severe manifestations of COVID19, a 
dysfunctional immune response is frequently observed.11 13 The immune system has co-evolved with a multitude 
of historical pathogens, inherent with redundancies to counteract pathogens which have developed multiple 
mechanism of immune evasion. This has led to the development of genetic differences and polymorphisms 
which may explain the variability of the immune response in some patients within the host immune pathway 
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(Supplementary Table 1). It is, therefore, critical to explore the intricacies of the pathways of the immune 
response to understand the differences in disease severity further. 
The immune response to viral infections is carefully orchestrated between the innate and adaptive responses, 
and various steps are required to attain control. Failure or suboptimal function of any of the components could 
lead to an inadequate response. The innate response initially recognizes pathogen-associated molecular 
patterns (PAMP) associated with viruses through pattern recognition receptors (PRR) in the tissue-resident 
antigen-presenting cells (APC), such as macrophages and dendritic cells (Figure 2). Examples of PRRs include 
Toll-like receptor (TLR) -7 & -13, which recognize single-stranded RNA,14 15 and RNA-sensing retinoic inducible 1 
gene (RIG-1). 16 Nod-like receptors (NLR) also help by sensing damage-associated molecular patterns.17 
Polymorphisms in the TLR and its downstream signaling molecules such as MYD88  may alter responses 
triggered PAMP recognition.18 19 20 The identification of viral pathogens by tissue macrophages initiates a 
cascade of cytokine secretion. These cytokines inactivate viral replication through type I interferons (IFN-a & 
IFN-b), and help activate the next line of innate immune defense, the natural killer (NK) cells, with their 
repertoire of activating and inhibiting receptors. The NK cell receptors include killer immunoglobulin-like 
receptors (KIR) and the lectin-like, NKG2 family of receptors, among others. KIR receptors recognize the down-
regulation of human leukocyte antigen (HLA) molecules on infected cells and mediate cytotoxicity. NKG2 
receptors recognize non-classical HLA molecules, such as HLA-E.21 22  
The innate immune effectors trigger a two-pronged HLA dependent adaptive immune response. The HLA genes 
exhibit extreme allelic polymorphisms and present viral peptides on host HLA molecules to T cells to trigger an 
adaptive immune response.  The T cell response involves both HLA class I and II molecules, which engage 
cytotoxic T cell (Tc) and helper T (Th) cell populations, respectively. The latter promotes both the cytotoxic T cell 
proliferation, as well as, B cell immunity and generation of SARS-CoV-2 specific antibodies.  Polymorphisms in 
the HLA molecules result in differential antigen binding and presentation, leading to variability in immune 
responses. Antibody production is the task of the B cell arm of the adaptive immune system, which with their 
unique B cell receptors, engage antigenic epitopes, either solubilized or directly presented by macrophages and 
dendritic cells.23 24 In response, B cells proliferate and differentiate into memory B cells and plasma cells 
facilitated by interaction with Th cells, establishing long term humoral immune response.25 This humoral 
immune response is crucial to providing control for any viral infection, including SARS-CoV-2. A subset of 
patients may not develop long-lasting antibodies and remains unclear if they are at risk for recurrent infection.26 
HLA & KIR, the master regulators of immunity 
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Polymorphisms in the HLA and KIR haplotypes may be responsible for the significant worldwide variability in the 
immune response to COVID19. In other viruses, genetic variation among HLA alleles and KIR confer differing 
susceptibility. For example, HLA-B*46:01 has been linked to the development and increased severity of SARS-
COV-1.27  HLA-A*02:05 may prevent HIV seroconversion, and HLA-B*52:01-HLA-C*12:02 had a protective effect 
on the progression of HIV in Japanese patients.28  A study using in silico modeling to predict viral peptide-MHC 
class I binding affinity across all known HLA -A, -B, and -C genotypes, has shown that HLA-B*46:01 has the fewest 
predicted binding peptides to SARS-CoV-2. This finding suggests that patients with HLA-B*46:01 may be at 
increased risk for infection with SARS-CoV-2.29  Thus, global haplotypes variation across populations may partly 
explain the difference in illness severity and case-fatality rates. A similar variety may be observed in the KIR 
haplotype frequencies. As an example, decreased KIR2DL2 expression has been linked to increased susceptibility 
to SARS-CoV-1 30 and KIR2DL3 homozygosity in association with its ligand HLA-C1, is associated with reduced 
disease progression of hepatitis C virus.31 The KIR2DL2 gene is present in 46% of Europeans and 80% of 
Ethiopians. 82% and 72% of these populations respectively are, at least, heterozygous for its ligand, C1. Similar 
HLA alleles and HLA epitope binding site effects have been observed in Dengue fever, transplant outcomes.32 33 
34 3536 
T cell and B cell repertoire diversity and symptom severity in COVID-19 patients  
In addition to these innate immune pathways, adaptive immunity with its T and B cell repertoire diversity is 
critical to mount an adequate immune response to viral infections. The mammalian T and B cell repertoire 
diversity and ability to recognize pathogen-derived antigens, either directly (B cell receptors) or upon 
presentation by HLA (T cell receptors), is derived from a unique process of T and B cell receptor gene 
rearrangement. Each of these genetic loci (for the immunoglobulin heavy and light chain and T cell receptor a & 
b loci respectively) are comprised of variable joining and diverse gene segments. These segments are 
recombined and further modified through the addition of non-templated nucleotides to yield an enormous 
repertoire of T and B cell receptor-bearing clones capable of recognizing the pathogens associated antigens with 
high precision and fidelity. A decline in repertoire diversity with age may create dominant oligoclonal T and B 
cell populations and predispose the elderly to develop symptoms with potentially higher severity of illness.37 38 39 
Further, inadequate T and B cell clonal responses in immunocompromised patients may put patients at risk for 
insufficient viral clearance, and a prolonged, severe, clinical course. As noted above, patients with COVID-19 
develop significant lymphopenia, which may be due to a pan-T cell-suppressive effect. 40 41 42 A reduction in 
circulating T cells may represent migration to the site of inflammation, hyperfunction, or direct virally mediated 
lethality, and it is known that T cells also express markers of exhaustion in the face of a severe viral infection. 33 43  
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Inflammatory cytokines during COVID-19  
Cytokines are key signaling molecules that orchestrate cellular and humoral immune responses to viral 
infections. The cascade of pro-inflammatory cytokines is triggered by the engagement of TLR on macrophages 
and by NK cells not finding their cognate autologous inhibitory ligands on infected cells. This first wave of pro-
inflammatory cytokines includes TNF-aIL-1, IL-2, IL-6, IL-15, and IFN-g. These stimulate Th cells to produce 
downstream cytokines, such as the pro-inflammatory IL-12, and 17, and the anti-inflammatory IL-4 and 10. 
These cytokines provide the critical third signal to trigger both Th and Tc responses to clear the infected cells. 
However, a generalized systemic inflammatory response may also be observed in viral infections. While optimal 
cytokine secretion will trigger an appropriate immune response, excessive cytokine release, i.e., “cytokine 
storm,” may develop in some patients with COVID-19, resulting in fulminant disease with high mortality. SARS-
CoV-2 may also infect monocytes and dendritic cells, altering the cytokine expression patterns and contributing 
to lymphopenia observed. 44 Importantly, this results in overproduction of inflammatory cytokines IL-6 and 
downstream release of MCP-1, VEGF, and IL-8, eventually culminating in a cytokine storm. Secondary 
hemophagocytic lymphohistiocytosis may ensue in these patients. Patients with severe disease have higher 
levels of IL-1, IL-6, IL-8, IL-10, and TNF-a compared with patients with milder disease.45 46 These high cytokine 
levels are associated with lymphopenia, with a deficit of both Th, Tc subsets, including naïve T cells and 
regulatory T cells.47 48 Elevated cytokine levels are also associated with a decrease in HLA-DR expression.42 In 
parallel, the NK cell population is also depleted, which may be the result of viral replication.49  While those with 
severe disease have significantly higher SARS-COV-2 RNA load and lymphopenia has directly correlated with viral 
load,50 these cytokine differences between moderately and severely ill patients may be due to polymorphisms in 
the cytokines involved. A quantitative approach relating differences in cytokine levels and polymorphisms in the 
immune response pathways may help identify patients at risk of severe disease.   
Immune response as a feed-forward process with signaling & effector components 
The immune response to infection may be broadly classified into a signaling component and an effector 
component, with the balance between the two determining the eventual outcome (Figure 3). The signaling 
function is determined by the cytokine and chemokine secretion by cells of the target tissues and the innate 
immune system in response to the infection. The effector component, on the other hand, is characterized by a 
pathogen-specific T and B cell response. The ability to maintain control of the virus and successfully recover 
from infection, relies on this sequential feed-forward loop nature of the signaling and effector components, with 
the virus attempting to inhibit these processes simultaneously. Mathematical models have been proposed to 
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understand the quantitative nature of these processes. These models generally study the growth of viruses as an 
exponential function of time.51 Viruses enter their host cells, grow exponentially in these cells, and are released 
into the surrounding milieu and infect an equal number of cells, where this exponential growth and release are 
repeated. Thus, viral replication exhibits exponential growth occurring in an exponentially rising number of 
target host cells until a limit is reached by target cell exhaustion. In SARS-CoV-2, because of the widespread 
expression of ACE-2, a large tissue reservoir is at risk of infection, amplifying the viral burden manifold over 
time. The corresponding immune response to the viral proliferation in the host has multiple components, and 
each of these components involves the growth of a population of immune effectors such as dendritic cells, NK 
cells, T cells, and B cells. The growth of each of these components will have to reach a threshold in an optimal 
period (e.g., by time, t1, t2, t3 or t, t’, t’’, t’’’ and so on for each cell type) to ensure timely and complete 
clearance of the virus (Figure 4). As the first line of defense, interferons slow down viral replication. 
Concomitantly, NK cells and cytotoxic T cells proliferate and kill infected cells but at different rates than the 
virus, driven by their receptor affinities.52 For NK cells, this represents the balance of inhibitory and activating 
signals from KIR and NKG2 family of receptors. In some individuals with a KIR B haplotype and a larger 
component of activating receptors, this may be a more effective process as opposed to those with a dominant 
component of inhibitory receptors. For the T cell responses, the ability of the HLA haplotype of the individuals to 
present SARS-CoV-2 derived peptides will be critical. This encompasses both the antigen-binding affinity of the 
HLA molecules in the host as well as antigen abundance. The requisite T cell response will be proportional to this 
antigen affinity and the affinity of the T cell receptor to the viral antigen-HLA complex. While the NK and T cell 
subset proliferation may catch up with an exponentially rising number of infected cells,53 cellular immunity may 
eventually fail under the pressure of rapidly replicating SARS-CoV-2, with widespread tissue involvement due to 
extensive ACE-2 expression. Thus, in addition to an efficient cellular immune response, a robust humoral 
immune response is essential to control and eliminate the infection eventually. The humoral response is 
characterized by a proliferating B cell and plasma cell population. Each plasma cell makes large amounts of 
pathogen-specific antibodies, which finally allows the host to match the growth rate of the virus and neutralize 
the viral particles being generated. Failure or suboptimal rate of any one of these pathways will lead to 
inadequate immune response and delay in viral clearance. The suboptimal response will potentially lead to 
earlier components in the pathway over-compensating for the failure of downstream mechanisms, caught in a 
feedback loop leading to phenomenon such as cytokine storm. The immune pathways are all susceptible to 
genetic polymorphisms that have functional consequences, such as variability in cytokine expression, antigen-
binding affinities, the strength of receptor ligation and downstream signaling. 54 55 56 Thus, functionally 
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consequential polymorphisms in these interconnected immune pathways may impede the development of an 
optimal immune response to COVID-19.  
Estimating the risk of severe illness with COVID19 
The immune response to viral infections is a multi-step, precisely coordinated process, which results in viral 
clearance through initial innate and later adaptive immune mechanisms. This has been modeled mathematically 
to a high level of precision using ordinary differential equations.57 58 59 The immune system behaves like a 
dynamical system when both T cells and NK cells are considered.60 61 62 63 Small changes in parameter values, for 
instance, in SARS-CoV-2 antigen – HLA binding affinity or the initial IL-6 or IFN-  levels produced in response to 
infection, may have a profound impact on the eventual clinical outcome.64 Thus, polymorphisms in critical 
immune response genes may alter the clinical outcome in a significant manner, mainly when they are 
considered together in a comprehensive mathematical description of the total immune response.  Quantifying 
the number of polymorphisms across variables can, therefore, be used to assess differences in disease risk. As 
such, it may be assumed that there are a set of variables (innate and adaptive) that confer an advantage in 
terms of viral clearance without cytokine storm and reduce the risk of severe disease, as compared to the set of 
variables with no common elements (Figure 5). In patients who have common elements across the entire set of 
immune response determinants (overlapping sets), the risk of severe disease may be equivalent when adjusted 
for age and comorbid conditions such as obesity, lung disease, and diabetes. Among patients who either have 
very few or no overlapping elements, the risk of disease may be significantly different.  
Dynamical systems modeling of the immune response to viral infections  
These considerations become evident in a thought experiment to model the growth of any virus. If rv is the viral 
growth constant (number of virions replicated, for each cell infected, for each iteration of the growth process), 
then the total viral burden V at time t can be given by the equation  
𝑉! ≈ 𝑟"𝐻(𝐼𝐸)𝑡 
Where H is the target tissue reservoir, and IE is the infection efficiency for that virus (proportion of virions that 
end up infecting a new cell). With an initial inoculum of 1000 viral particles, 100 cells (H) get infected (IE=0.1 or 
10%); in the second iteration 100000 virions will be produced with 10,000 cells infected, and it this keeps 
growing over time t until the limit of H is reached. Interferon (IFN) would directly suppress V, by a fraction, sc 
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(cytokine-induced suppression), starting at a later time t’ (t’ < t), and depending on how IFN much is produced, 
modifies Vt to Vt(IR) (diminished viral burden following the immune response) 
𝑉!($%) ≈ 𝑟"𝐻(𝐼𝐸)𝑡 '(!!" ……… [1] 
Along with IFN production, a cascade of cytokine signaling will also be initiated, by the tissue-resident dendritic 
cells (DC) as well as the innate immune cells migrating into the tissues,  
𝐷𝐶 ≈ (𝜙) + ∆𝜙)𝑒*!"𝑉 …….[2] 
Where c is the unit production of cytokine per unit increase in V. 𝜙0 are the tissue-resident macrophages, and 𝜙 
are the macrophages/inflammatory cells that migrate into the tissues. DC then is the dendritic cell (𝜙) 
production of cytokines in response to V. As V gets larger, DC gets higher with t and constitutes the feed-forward 
loop depicted in Figure 3 and Figure 6. Unless the overall feedback loop depicted in Figure 3 slows down the 
growth of V over time, this can lead to cytokine storm. It is also important to note that DC is a vector matrix 
made up of many different cytokines, which all work on their respective receptors in the different target cell 
populations. 
The cytokines will trigger an NK cell response, which will slow down V. Of note, this variable, and others, 
represent growth or change over time and is more accurately referred to by dV/dt. Still, for simplicity, we will 
simply consider absolute value Vt. NK cell growth and response may be considered as a function of the sum of 
activating and inhibitory receptors, the KIR and the NKG2 family of receptors. These are modeled as vector-
operator equations, where the NK cell with its KIR molecules constitutes a ‘vector,’ and the target with its KIR-
ligand molecules, an operator. The ‘operator’ modifies the ‘vector’ upon interacting with it; for example, it may 
either inhibit or activate it. Each individual KIR-KIRL interaction may be described as follows; if an inhibitory KIR 
(iKIR) on the NK cell encounters a ligand on its target, this results in an interaction which may be scored, (−1) × (1) = −1, this will give the NK cell an inhibitory signal, assuming constitutively active basal state for NK 
cells; if there is no ligand for an inhibitory KIR, i.e., missing KIRL (mKIRL), the interaction score will be  (−1) × (−1) = +1 because of the abrogation of the inhibitory signal, and finally, activating KIR (aKIR) 
interacting with its ligands will be scored, (1) × (1) = +1, when the ligand is present, and (1) × (0) = 0,	when 
the ligand is absent since no signal is given. Each of these different scores constitute a distinct component of the 
total KIR effect on individual NK cells expressing them, and while aKIR and iKIR function independently the 
cumulative effect calculated by taking their sum, determining the eventual outcome of NK cell- target 
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interaction. Activating KIR are not required for a robust NK cell immune response in most instances, evident as 
individuals with haplotypes containing no functional aKIR are common and even people with haplotypes that 
include aKIR have NK cells in their NK cell repertoire without any aKIR present.65 Depending on the degree to 
which the virus down regulates HLA class I molecules to evade Tc mediated killing, it may lead to iKIR-missing KIR 
ligand mediated killing or may not through viral immune escape mechanisms such as, no HLA class I down 
regulation or HLA decoy expression. Though viral evasion through decoy HLA expression can lead to NK cell 
medicated viral killing as in m157 protein expression by mice with mouse CMV infection. M157 has been shown 
to strongly associate with an activating mouse LY49 receptor (analogous to KIR) and confer host protection 
against MCMV.66 So, the NK cell effect may be summarized by 
𝑁𝐾!""≈ (𝑁𝑒+(,-./,-.0)) ∗ 𝑁𝐾)(𝑁𝑒+(,-./,-.0) −𝑁𝐾!""/')(𝑒/1(23)!"") + 1 
In this equation, NKt is the number of NK cells at time t, N is the growth constant for NK cells, S KIR-KIRL is the 
sum of activating and inhibitory KIR-KIR L interactions described above. The growth exponent r(NK) is the 
cytokine-driven and intrinsic growth rate of NK cells. NKt will reduce Vt by a certain fraction as well, so equation 
1 becomes,  
𝑉!(#$%&%') ≈ 𝑟)𝐻(𝐼𝐸)𝑡( *+!!"&%'#!"")……. [3] 
Here time, t’’ is a later period in time at which the NK cell effect becomes manifest, it is later than the time, t 
when viral proliferation begins. This means that the impact of an immune checkpoint triggered later than t (i.e., 
t’ and t’’) will require for those processes to outpace the viral proliferation, which already had a lead on these in 
time. 
The resulting viral infection and cytokine secretion trigger the adaptive immune response. In the adaptive 
response, the antigen-presenting cells (APC) present viral antigens on HLA molecules to the Tc and Th cells.  The 
unique T cell receptors (TCR) engage the cognate HLA-viral antigen complex. The binding affinity of these 
antigens to the HLA molecules varies over a broad spectrum, as does the affinity of the TCR for their cognate 
antigen-HLA complexes. A library of viral peptides may thus be presented on HLA molecules and trigger a 
polyclonal T cell response. A system of vector-operator matrices with the logistic equation of growth governs the 
behavior of each T cell clone.  
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𝑇𝑐4!"""≈ (𝑚5𝑇𝑒6#$∗89%$) ∗ 𝑇𝑐4)(𝑚5𝑇𝑒6#$∗89% − 𝑇𝑐4!"""/')(𝑒/1(8)!""") + 1 
This equation describes the growth of a single clone of CD8+ Tc cells, where aiI is the binding affinity of the ith 
SARS-CoV-2 antigen to HLA class I molecules, mi is the expression level of the protein from which the ith peptide 
is derived, and TCR is the binding affinity of the TCR of jth Tc cell clone to the antigen-HLA complex. The 
coefficient T represents the growth constant for T cells. Analogously, CD4+Th cells will have apII as the afiinity of 
the pth antigen for specific HLA class II molecule, which along with the affinity of the qth TCR for the antigen-HLA 
complex, and the expression of this protein determine the final cell number for qth Th cell clone upon 
stimulation by target pth antigen. It is to be noted that the starting time here is different, t’’’ < t. Each individual 
depending on their HLA types will thus have a different library of SARS-CoV-2 peptides that they will present to 
their Th and Tc cells. Further, Th cells modulate Tc and B cell proliferation and differentiation, and therefore 
their role may be described as a vector transformation function, changing the jth T cell clone at time t’’’ from 𝑇𝑐4!""" 	to 𝑇𝑐4′!""".  
𝑇ℎ:!"""≈ (𝑚;𝑇𝑒6%$$∗89%&) ∗ 𝑇𝑐:)(𝑚;𝑇𝑒6%$$∗89%& − 𝑇𝑐:!"""/')(𝑒/1(8)!""") + 1 
𝑇𝑐4′!"""≈𝑇ℎ:!""" ∗ 𝑇𝑐4!"""  
As noted, these libraries of antigens bound to HLA molecules are also modeled as operator matrices, which tend 
to vary between individuals with different HLA types and the T cell clones are modeled as vector matrices. The T 
cell responses are amplified by the cytokines secreted by the APC growing and generally tend to peak before 
plateauing. While the Tc are capable of precisely recognizing infected cells and destroying them, here, the 
growth is occurring on a different scale of magnitude altogether, compared to the growth and infection rate of 
virions. This differential magnitude occurs because each of the T cell clones starts with a very low number of 
cells (theoretically a single cell) when it first encounters cognate antigen.  
The adaptive immune component is equipped to deal with rapidly replicating viruses through B cells. Each B cell 
makes millions of virus-neutralizing antibody molecules, so once B cell immunity sets in, it may effectively 
compete with viral growth through antibody secretion. There, too, an element of time is crucially involved, as 
the B cells with the appropriate B cell receptor (BCR) encounter the viral epitopes and get selected for 
expansion. This is, once again, a polyclonal process, with the affinity of the kth antigen for the lth BCR driving the 
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B cell clonal expansion, as in the case of T and NK cells. The expanded B cell clones under the influence of Th 
cells undergo somatic hypermutation to further fine-tune the BCR affinity for the kth antigenic epitope yielding a 
modified lth BCR’. As these B cells proliferate, they produce large amounts of antibodies against the antigenic 
epitope k, Il, which over time, catches up and neutralizes V, even though antibody secretion had started at time 
t’’’’ much later than t, when viral proliferation had started. 
𝑉!($%) ≈ 𝑟"𝐻(𝐼𝐸)𝑡 ? 1𝑠*𝑡< + 𝐷𝐶	(𝑁𝐾!𝑡<< + (∑ 𝑇ℎ:;' 𝑡<<<B∑ 𝑇𝑐45' 𝑡<<< +∑ 𝐵=𝐼=>' 𝑡<<<<D))E 
The above equations outline the two possible innate and adaptive immune response scenarios to a viral 
infection that unfolds as time progresses, from t®t’®t’’®t’’’®t’’’’. If this response controls the viral infection 
such that the actual viral load, Vt ≈ Vt(IR), with the viral load optimally eliminated, the signaling cascade, DC 
(Equation 2), will be dampened and clinical course is optimal.  If, on the other hand, Vt >Vt(IR), persistent Vt will 
continue to drive the DC in a feed-forward loop culminating in a cytokine storm. In light of the above discussion, 
another mechanism for cytokine storm in the former situation (with optimal, timely viral control) will be 
autologous tissue destruction perpetuating the cytokine cascade in a different feedback loop. It is important to 
recognize that DC is a matrix, where many different cytokines with both suppressive as well as growth 
promoting effects are represented.67 Thus the overall effect of DC on T cell or B cell growth is not always in the 
positive direction, rather depending on the cytokines dominating in the milieu at any given time one may 
observe growth suppression, a phenomenon commonly seen in severely ill COVID19 patients. The whole 
immune cascade may thus be mathematically described as a system of matrix vector operator equations. This 
schematic depicted in Figure 6. 
Inferences from the dynamical systems modeling of viral disease 
This exercise demonstrates the multiplicity of responses involved in controlling infections in general, as it is in 
this particular case. Further, they indicate the many redundant pathways at work in the immune response to the 
same. It is also imperative to note that pathogens have evolved mechanisms to evade the immune response at 
multiple checkpoints. Because of genetic variation, not all individuals are equally well endowed with the ability 
to control infection. A multi-targeted approach may be needed to overcome the redundancies encountered. The 
notion of performing randomized trials with a single intervention tested at a time is at the heart of medicine, 
and agents are failing such trials are often discarded for not having met efficacy endpoints. The thought 
experiment above suggests that for a pathogen that has the capability of outpacing or disabling several different 
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immune mechanisms, a combination of many agents and modalities may be required to control the disease. 
Attention to this aspect of infectious disease management needs to be given in future trial design.   
A quantitative approach, such as outlined here, may be used to identify variation in immune response and 
genetic components that may be responsible for the range of illness severity that is observed in COVID-19. 
Obtaining a better understanding of the differences in the host response is vital to identify those at risk for 
developing severe disease and target treatment strategies.  
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Figures.  
Figure 1. A. COVID-19 population-adjusted incidence in US states as of 4/7/2020. (E. Krieger, personal 
communication, source: https://covid19.healthdata.org/united-states-of-america). Adjusted for population and 
each state graph started when it reached 0.5 persons/100,000 people. (Y-axis: Total COVID19 cases/state (log 
scale), X-axis: Time in days). B. The case fatality rate of COVID19 across the world. Note Log-Log scaling, and 
different countries occupy different slopes corresponding to variable case-fatality (source: 
https://coronavirus.jhu.edu/data/mortality).  
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Figure 2. A schematic of the overall immune response to a viral infection in a healthy individual. Box (dashed 
line) represents the lymph node. The immune response destroys cells with disrupted margins. Time goes from t0 
to t5 in this optimal scenario. APC: Antigen-Presenting Cell, DC: Dendritic Cell 
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Figure 3. The magnitude of the immune response to viral burden over time and its components determine 
clinical outcome. 
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Figure 4. Quantitative model of antiviral immune response, demonstrating the evolution of innate and adaptive 
immune responses. ∑ 𝑇𝑐?) , ∑ 𝑇ℎ@) 	&	 ∑ 𝐵A<)  denote the sum of x, Tc; y, Th and z’, somatically hypermutated B cell 
clones. 
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Figure 6. Vector operator model to illustrate the quantitative  
 
A. Viral replication drives the signaling function  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Differential impact of cytokines interactions with cytokine receptors with + and – growth effects on 
single immune effector cells. 
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C. Differential impact of cytokines on immune effector cell subsets with + and – growth effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. Differential impact of viral antigens binding affinity to HLA class I, II and BCR on immune effector cell 
clonal growth.   
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Figure 5. Schematic showing the two scenarios, one with overlapping genetic traits vs. distinct genetic traits, 
with differential susceptibility to COVID-19. 
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Supplementary Table 1. List of polymorphisms in immune regulatory genes. 
Cytokine Polymorphism Associated syndrome 
Interferon 
alpha 
IFNL3- rs8099917 
Ss46915590 
Rs1176484441 
Rs368234815 
IL28B 
Ss469415590 
Rs12979860 
 
Rs1332190 (IFNA1) 
RS 3032182 
 
Rs2843710 (IFN AR1)3 
 
Rs2243594 A/G 
Rs1012335 G/C 
Rs2257167 G/C 
Rs 2843710 C/G 
Rs2850015 C/T 
+6993 C/T 
 
Rs1332190 (IFNA1) 
Rs9298814 (IFNA17) 
 
IFNAR1_30127 (rs2254315, rs17875857) 
IFNAR1_18339 (rs2257167, rs17875817) 
 
JAK1 
Rs11208534 
Rs2780831 
Rs310196 
Rs669260 (DDX58) 
 
Rs368234815 
HCV- response to IFN and ribavirin 
treatment4 
 
 
 
 
 
 
Chronic hepatitis B5 
 
 
Enterovirus 71 
 
Plasmodium falciparum malaria6 
 
 
 
 
 
 
Crimean-Congo Hemorrhagic Fever7 
 
 
HIV8 
 
 
 
 
Dengue9 
 
 
 
 
 
Increased risk of TRM after HCT10  
and viral reactivation after autologous  
HCT11  
Interferon 
beta 
Rs2304237 
Rs2071430 
Rs17000900 
SARS-CoV-112 
Interferon 
gamma 
Rs12979860 
Rs368234815 
 
Rs2069705 T/G 
Hepatitis C 
 
 
Plasmodium falciparum malaria 
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Rs2430561 A/T 
Rs3138557 (CA)n 
Rs2069718 T/C 
Rs2068727 A/G 
Rs2069728 G/A 
 
Rs1859330 (OAS3) 
 
IFNGR1T-56-C 
 
IFGN -1616, +3234 
IFN -2109 A/G13 
 
Rs2430561 
 
 
 
 
 
 
 
 
 
 
               Rs12369470 
Rs 2406918 
 
Rs3888188 (IFITM3) 
Rs1861494 
Rs2069718 
Rs2430561 
 
 
 
OAS1-rs10774671, rs34137742 
 
Rs2430561 
 
 
 
 
 
 
Enterovirus 7114,15 
 
Non-tuberculous Mycobacteria16 
 
Mycobacteria tuberculosis17 
 
 
Chlamydia trachomatis18 
Mycobacteria tuberculosis19,20 
Hepatitis B21 
Hepatitis C22 
Cytomegalovirus23,24 
BK virus25 
Leprosy26 
Chagas Disease27 
Toxoplasmosis retinochoroiditis28 
Dengue29 
 
BK virus25 
 
 
Mycobacteria tuberculosis30,31 
 
 
 
 
 
 
West Nile Virus29 
 
 
Increased severity of GVHD after HCT32 
HLA HLA-DOA rs1044429 
HLADOB rs2284191 
Rs2856997 
HLA-DMA rs1063478 
HLA-DMB rs23544GG 
Rs4273729 
 
HLA-B*46:01 
 
HLA-B*15:18 
Hepatitis C33-35 
 
 
 
 
 
 
SARS-CoV-2, SARS CoV-136 
 
HIV37-39 
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HLA-B*44:02  
HLA-B*67:01 
HLA-B*15:01G 
HLA-DRB1*14:01 
HLA- DRB1*13:02 
HLA- DRB1*12:01 
HLA-A*02:06 
 
HLA-A*25:01 
HLA-C*01:02 
 
HLA-A*11 
HLA-B*35  
HLR-DRB1*10 
 
HLA-A*0203 
HLA-A*24 
HLA-A*33 
HLA-DRB1*03 
HLA-DRB1*09 
HLA- DRB1*11 
 
HLA-B*46 
HLA-B*46-DRB1*09 
HLA-B*51-DRB1*09 
 
Rs872956 (HLA-DPB1) 
Rs9277535A (HLA-DPB1) 
HLA-B*15 
HLA-DRB1*11 
HLA-DRB1*14 
HLA-DQ rs9275572, rs2856718 
HLA-DQB1&05:02 
HLA-DQB1*05:03 
HLA-DQB1*0601 
 
HLA-DRB1*030101 
HLA-DRB1*130101 
HLA- DRB1*040101 
HLA-DRB1*040501  
HLA- DRB1*7:01:01 
HLA- DRB1*110101 
HLA-DQ rs9275572, rs2856718 
HLA-G rs1063320 
 
HLA-DQB1*0303 
 
HLA-DQB1*0401 
 
 
 
 
 
 
 
 
SARS-CoV-236 
 
 
H1N1 Influenza40 
 
 
 
Dengue41 
 
 
 
 
 
 
Hantaan virus42 
 
 
 
Hepatitis B43-47 
 
 
 
 
 
 
 
 
 
Hepatitis C46,48,49 
 
 
 
 
 
 
 
 
Helicobacter pylori50, Chikungunya51 
 
Helicobacter pylori50, Hepatitis B47 
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HLA-DQA1*0103 
HLA-DQ*0301 
 
HLA-E*0101/0101 
HLA-G rs16375 
 
Helicobacter pylori50 
 
 
Cytomegolovirus52,53 
TLR TLR2 Arg753Gln 
TLR2 rs5743709 
TLR9 rs187084 
TLR4 rs4986781 
 
TLR2 delta 22 
 
TLR4 asp299gly 
 
TLR2 arg677trp,  
 
TLR arg753gln 
 
 
 
TLR3 leu412phe 
 
 
TLR4 
 
TLR4 rs4986790 
TLR4 rs4986791 
TLR4 rs2149356 
 
TLR4 399 C 
 
TLR4 rs11536889 
 
TLR-7 (rs3853839) 
TLR-7 IVS1+1817G/T 
TLR-7 c.4-141A/G 
‘ 
TLR-8 (rs 3764879) 
 
TLR-9 (rs352139) 
 
TLR-1 rs5743551 G/G 
TLR-8 rs3764879 
 
TLR-1 rs5742611 
 
TLR-4 +3725G/G 
Mycobacteria tuberculosis54-57 
 
 
 
 
Plasmodium falciparum58 
 
Influenza59, HIV60, cytomegalovirus61 
 
cytomegalovirus61 
 
Influenza59, Echinococcus62, 
Mycobacteria tuberculosis63 
Cytomegalovirus59 
 
Influenza59, Cytomegalovirus64, 
Japanese Encephalitis Virus65 
 
Respiratory Syncytial Virus66 
 
Hepatitis C67,68 
 
 
 
Hepatitis E69 
 
Hepatitis A70 
 
Chikungunya71 
Crimean Congo Hemorrhagic fever72 
 
 
Chikungunya71 
 
Plasmodium falciparum73 
 
Increased TRM after HCT74 
 
Increased grade II-IV aGVHD after 
HCT75 
 
Decreased TRM after HCT76 
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IL1 TIRAP 180L 
 
IL-1B +3954 C/T 
 
IL-1RN*1/*1 
IL-1RN*2 
 
IL-1B +3954 C/T 
Recurrent pneumococcal LRTI77 
 
sepsis (protective)78 
 
Chikungunya79 
 
 
Increased aGVHD after HCT80 
IL6 Rs1800795 
 
Rs1800796 
 
Rs1800795 
Rs1800797 
Septic shock from pneumonia81 
 
Mycobacteria tuberculosis82 
 
Increased rate of aGVHD after HCT83,84 
KIR KIR 2DL3 
KIR 2DL5 
KIR 2DL2 
KIR 2DS1 
KIR 3DS1 
 
Haplotype B/x 
KIR 2DL2 and 2DS2 
HIV 85,86 
 
 
 
 
 
Increased cGVHD after HCT87 
Increased aGVHD after HCT88 
TNF alpha TNF857 C/C 
TNF 238 A/A 
 
TNF -308A 
 
 
 
 
 
 
TNF 863C 
 
rs1800629 
rs1799724 
 
857 C/T 
 
RS361525(A) 
 
Rs1800629 
Mycobacteria tuberculosis13 
 
 
Toxoplasmosis retinochoroiditis28 
Septic shock from pneumonia81 
Schistosomiasis89 
Hepatitis B90 
Post-operative sepsis91 
Japanese Encephalitis Virus92 
 
Japanese Encephalitis Virus92 
 
Hepatitis C93,94 
 
 
Hepatitis B90 
 
Increased aGVHD risk after HCT95 
 
Sepsis risk96 
NOD Rs2284358 
Rs2970500 
Cytomegalovirus97 
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Rs10267377 
 
LRRKrs1873614 
Rs1873613GG 
RIPK rs40457, rs42490 
 
NOD2/Card2 variants 
 
Toxoplasmic retinochoroiditis98 
 
Mycobacterium leprae99 
 
 
 
Increased TRM after HCT100  
 
Abbreviations: aGVHD=acute graft versus host disease, cGVHD=chronic graft versus host disease, 
TRM=treatment related mortality, HCT=hematopoietic stem cell transplant, LRTI= lower respiratory tract 
infection, HIV = human immunodeficiency virus. SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.  
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